Search

Your search keyword '"Duh, Mei Sheng"' showing total 1,336 results
Start Over Author "Duh, Mei Sheng"
1,336 results on '"Duh, Mei Sheng"'

12. Treatment Patterns and Clinical Outcomes Among Patients With Metastatic Prostate Cancer Harboring Homologous Recombination Repair Mutations

Author

Bobbili, Priyanka J., Ivanova, Jasmina, Solit, David B., Mettu, Niharika B., McCall, Shannon J., Dhawan, Mallika, DerSarkissian, Maral, Arondekar, Bhakti, Chang, Jane, Niyazov, Alexander, Lee, Jocelyn, Huq, Risha, Green, Michelle, Turski, Michelle, Lam, Phu, Muthukumar, Aruna, Guo, Tracy, Mohan, Manasi, Zhang, Adina, Duh, Mei Sheng, and Oh, William K.

Published
2024
Full Text
View/download PDF

20. Clinical Outcomes Among Patients With Metastatic Pancreatic Ductal Adenocarcinoma Treated With Liposomal Irinotecan

Author

Yu, Kenneth H, Hendifar, Andrew E, Alese, Olatunji B, Draper, Amber, Abdelrahim, Maen, Burns, Ethan, Khan, Gazala, Cockrum, Paul, Bhak, Rachel H, Nguyen, Catherine, DerSarkissian, Maral, Duh, Mei Sheng, and Bahary, Nathan

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Oncology and Carcinogenesis, Pancreatic Cancer, Cancer, Clinical Research, Digestive Diseases, Clinical Trials and Supportive Activities, Rare Diseases, 6.1 Pharmaceuticals, Evaluation of treatments and therapeutic interventions, cancer management, liposomal irinotecan, metastasis, pancreatic cancer, pancreatic ductal adenocarcinoma, Clinical sciences, Oncology and carcinogenesis
Abstract

BackgroundThe NAPOLI-1 trial demonstrated that liposomal irinotecan in combination with fluorouracil (5-FU) and leucovorin (LV) prolonged survival with a manageable safety profile in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) previously treated with gemcitabine-based therapy. Real-world data on clinical outcomes associated with liposomal irinotecan in NAPOLI-1-based regimens is needed to further substantiate this.MethodsThis real-world, retrospective chart review study included patients with mPDAC who received NAPOLI-1-based regimens from six academic centers in the United States. Liposomal irinotecan initiation defined the index date. Overall survival (OS) and progression-free survival (PFS) were assessed with Kaplan-Meier methodology.ResultsThere were 374 patients evaluated; median age was 68 years, and 51% were female. Among 326 patients with baseline ECOG information, approximately 74% had ECOG score

Published
2021

25. Costs and Treatment Patterns Among Patients with Atopic Dermatitis Using Advanced Therapies in the United States: Analysis of a Retrospective Claims Database

Author

Eichenfield, Lawrence F, DiBonaventura, Marco, Xenakis, Jason, Lafeuille, Marie-Helene, Duh, Mei Sheng, Fakih, Iman, Levenberg, Mark, Cappelleri, Joseph C, and Sikirica, Vanja

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Clinical Research, 6.1 Pharmaceuticals, Evaluation of treatments and therapeutic interventions, Good Health and Well Being, Atopic dermatitis, Corticosteroids, Costs, Dupilumab, Immunosuppressants, Phototherapy, Clinical sciences
Abstract

IntroductionFor many, atopic dermatitis (AD) is not adequately controlled with topical regimens. This analysis examined treatment using advanced therapies and associated costs.MethodsThe IQVIA Health Plan Claims data set was analyzed. Patients aged ≥ 12 years with AD who newly initiated advanced therapy after the availability of dupilumab (March 28, 2017) and had ≥ 6 months continuous enrollment before and after their first advanced therapy claim (index date) were included. Advanced therapies included dupilumab, systemic corticosteroids (SCSs), systemic immunosuppressants (SISs), and phototherapy. A multivariate regression model was used to predict annualized follow-up healthcare costs.ResultsIn total, 1980 patients were included (61.1% female; mean age, 41.2 years [SD, 17.4]; 11.3%

Published
2020

30. Efficacy of avapritinib versus best available therapy in the treatment of advanced systemic mastocytosis

Author

Reiter, Andreas, Gotlib, Jason, Álvarez-Twose, Iván, Radia, Deepti H., Lübke, Johannes, Bobbili, Priyanka J., Wang, Aolin, Norregaard, Chelsea, Dimitrijevic, Saša, Sullivan, Erin, Louie-Gao, Melinda, Schwaab, Juliana, Galinsky, Ilene A., Perkins, Cecelia, Sperr, Wolfgang R., Sriskandarajah, Priya, Chin, Andi, Sendhil, Selvam R., Duh, Mei Sheng, Valent, Peter, and DeAngelo, Daniel J.

Published
2022
Full Text
View/download PDF

31. Real‐World Treatment Patterns and Clinical Outcomes in Advanced Gastrointestinal Neuroendocrine Tumors (GI NET): A Multicenter Retrospective Chart Review Study

Author

Kulke, Matthew H, Benson, Al B, Dasari, Arvind, Huynh, Lynn, Cai, Beilei, Totev, Todor, Roesner, Nina, Duh, Mei Sheng, Neary, Maureen P, Maurer, Victoria E, Shih, Brandon E, Dagohoy, Cecile G, Chan, Jennifer, and Bergsland, Emily K

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Oncology and Carcinogenesis, Clinical Research, Cancer, Digestive Diseases, Evaluation of treatments and therapeutic interventions, 6.1 Pharmaceuticals, Aged, Antineoplastic Combined Chemotherapy Protocols, Chemoradiotherapy, Disease Progression, Embolization, Therapeutic, Female, Follow-Up Studies, Gastrointestinal Neoplasms, Humans, Interferon-alpha, Kaplan-Meier Estimate, Male, Medical Records, Middle Aged, Neuroendocrine Tumors, Peptides, Cyclic, Practice Patterns, Physicians', Radiopharmaceuticals, Retrospective Studies, Somatostatin, Tertiary Care Centers, Treatment Outcome, Gastrointestinal neuroendocrine tumor, Treatment patterns, Somatostatin analogs, Real-world analysis, Real‐world analysis, Oncology & Carcinogenesis, Oncology and carcinogenesis
Abstract

BackgroundWe assessed treatment patterns and outcomes of patients with advanced gastrointestinal (GI) neuroendocrine tumors (NET) at four large tertiary referral centers in the U.S.Patients and methodsWe performed a retrospective chart review of patients aged ≥18 years at advanced GI NET diagnosis, treated between July 2011 and December 2014. Index date was the histologically confirmed diagnosis date of locally advanced/metastatic GI NET. Data included baseline characteristics, treatment patterns, progression, death, and GI NET-related health care resource utilization from index date through last contact or death. Time-to-event analyses, including treatment discontinuation, progression, and overall survival (OS), were performed using Kaplan-Meier analysis.ResultsWe identified 273 patients; 156 (57%) had primary ileum NET, and 174 (64%) had functional NET. First-line treatments included somatostatin analog (SSA) alone (89%) or in combination (2%), liver-directed therapy (LDT; 8%), and cytotoxic chemotherapy or interferon (2%). One hundred fifty-five patients continued with second-line therapy, including SSA alone (17%) or in combination (75%, with 3% combined with peptide receptor radionuclide therapy), LDT (4%), and other treatments (3%). Median time (months) to first-line discontinuation was 154.0 for SSAs and 3.8 for cytotoxic chemotherapy. Overall median time to investigator-assessed progression following treatment initiation was 30.3 months. Median OS (months) following first-line initiation was 151.8 for all patients and 178.9 for first-line SSA.ConclusionOur study illustrates the common use of SSAs in both first-line and subsequent treatment of patients with GI NETs, as well as the relatively long survival durations and multiple additional treatments received by patients with this condition. Treatment pattern assessment at later times, following approval of newer treatments, is warranted.Implications for practiceThis study, assessing treatment patterns over a period of up to 30 years, showed that SSAs, LDT, cytotoxic chemotherapy, and interferon are common treatments for advanced GI NETs. SSAs alone or in combination with other treatments were the most frequent therapy in first and subsequent lines. Patients in this study remained on SSAs long-term, with median treatment duration of 12.8 years in first line. Treatment patterns should be assessed beyond this study's time period, given recent U.S. Food and Drug Administration approvals for additional treatments for GI NET, which will likely be incorporated in the continuum of care of patients.

Published
2019

32. Treatment Patterns and Clinical Outcomes in Advanced Lung Neuroendocrine Tumors in Real‐World Settings: A Multicenter Retrospective Chart Review Study

Author

Dasari, Arvind, Bergsland, Emily K, Benson, Al B, Cai, Beilei, Huynh, Lynn, Totev, Todor, Shea, Jerome, Duh, Mei Sheng, Neary, Maureen P, Dagohoy, Cecile G, Shih, Brandon E, Maurer, Victoria E, Chan, Jennifer, and Kulke, Matthew H

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Oncology and Carcinogenesis, Digestive Diseases, Liver Disease, Cancer, Clinical Research, Evaluation of treatments and therapeutic interventions, 6.1 Pharmaceuticals, Aged, Antineoplastic Combined Chemotherapy Protocols, Carcinoid Tumor, Chemoradiotherapy, Disease Progression, Embolization, Therapeutic, Everolimus, Female, Follow-Up Studies, Humans, Kaplan-Meier Estimate, Lung Neoplasms, Male, Medical Records, Middle Aged, Practice Patterns, Physicians', Radiopharmaceuticals, Retrospective Studies, Somatostatin, Tertiary Care Centers, Treatment Outcome, Lung neuroendocrine tumor, Treatment patterns, Somatostatin analogs, Real-world analysis, Real‐world analysis, Oncology & Carcinogenesis, Oncology and carcinogenesis
Abstract

BackgroundUsing data from four tertiary referral centers in the U.S., we assessed real-world treatment patterns and clinical outcomes of patients with advanced lung neuroendocrine tumors (NETs).Subjects, materials, and methodsWe performed a retrospective chart review of adult patients with locally advanced/metastatic (typical/atypical) lung NETs treated between July 2011 and December 2014. Index date was histologically confirmed typical/atypical carcinoid tumor diagnosis date. Data included baseline characteristics, treatment patterns, progression, death, and lung NET-related health care resource use from index date through last contact/death. Time to treatment discontinuation and first progression, time from first to second progression, and overall survival (OS) were estimated using Kaplan-Meier analysis.ResultsWe identified 83 patients; 19 (23%) had functional NET. First-line treatments included somatostatin analogs (SSAs) alone (56%) or in combination with other therapies (6%), cytotoxic chemotherapy (20%), external beam radiation therapy (EBRT) (9%), liver-directed therapy (LDT) (4%), and everolimus/other (5%). Sixty patients had second-line therapy including SSA alone (18%) or in combination (40%), cytotoxic chemotherapy (17%), everolimus (12%), LDT (7%), EBRT (3%), and other treatments (3%). Median time (months) to first-line discontinuation were as follows: SSAs, 43.3; cytotoxic chemotherapy, 3.6. Overall median time (months) to investigator-assessed progression following treatment initiation was 12.4. Median OS (months) following treatment initiation was 66.4 for all patients and 81.5 for patients receiving SSAs.ConclusionSSAs, alone and in combination, are common treatments for advanced lung NETs. Patients have additional treatment options and relatively long survival compared with patients with other advanced cancers. Treatment pattern assessment following approval of newer treatments is needed.Implications for practiceSomatostatin analogs (SSAs), cytotoxic chemotherapy, EBRT, liver-directed therapy, and targeted therapies are common treatments for locally advanced/metastatic (typical/atypical) lung neuroendocrine tumors (NETs). SSAs alone or in combination with other treatment modalities were the most common first- and second-line therapy, followed by cytotoxic chemotherapy. Patients continued treatment with SSAs long-term with median treatment duration of 43 months. Median overall survival was 66 months following initiation of first-line therapy for all patients. Treatment pattern assessment beyond the time period of this study is needed given recent U.S. Food and Drug Administration approvals for additional treatments for lung NETs that will likely be incorporated in the treatment landscape.

Published
2019

37. Herpes zoster burden in patients with asthma: real-world incidence, healthcare resource utilisation and cost

Author

Singer, David, primary, Thompson-Leduc, Philippe, additional, Ma, Siyu, additional, Gupta, Deepshekhar, additional, Cheng, Wendy Y, additional, Muthukumar, Aruna, additional, Devine, Francesca, additional, Sundar, Manasvi, additional, Bogart, Michael, additional, Hagopian, Ella, additional, Poston, Sara, additional, Duh, Mei Sheng, additional, and Oppenheimer, John J, additional

Published
2024
Full Text
View/download PDF

46. Burden of Herpes Zoster Among Patients with Psoriatic Arthritis in the United States

Author

Singer,David, Thompson-Leduc,Philippe, Ma,Siyu, Gupta,Deepshekhar, Cheng,Wendy Y, Sendhil,Selvam, Sundar,Manasvi, Hagopian,Ella, Stempniewicz,Nikita, Duh,Mei Sheng, Poston,Sara, Singer,David, Thompson-Leduc,Philippe, Ma,Siyu, Gupta,Deepshekhar, Cheng,Wendy Y, Sendhil,Selvam, Sundar,Manasvi, Hagopian,Ella, Stempniewicz,Nikita, Duh,Mei Sheng, and Poston,Sara

Abstract

David Singer,1 Philippe Thompson-Leduc,2 Siyu Ma,1,3 Deepshekhar Gupta,4 Wendy Y Cheng,5 Selvam R Sendhil,6 Manasvi Sundar,6 Ella Hagopian,5 Nikita Stempniewicz,1 Mei Sheng Duh,5 Sara Poston1 1GSK, US Health Economics and Outcomes Research, Philadelphia, PA, USA; 2Analysis Group, Inc., Health Economics and Outcomes Research, Montreal, QC, Canada; 3Tufts Medical Center, Boston, MA, USA; 4Analysis Group, Inc., Health Economics and Outcomes Research, Menlo Park, CA, USA; 5Analysis Group, Inc., Health Economics and Outcomes Research, Boston, MA, USA; 6Analysis Group, Inc., Health Economics and Outcomes Research, Los Angeles, CA, USACorrespondence: Nikita Stempniewicz, GSK, US Health Economics and Outcomes Research, FMC Tower Suite 1700, 2929 Walnut Street, Philadelphia, PA, 19104, USA, Tel +1 203 803 9909, Email nikita.x.stempniewicz@gsk.comPurpose: Patients with psoriasis (PsO) and psoriatic arthritis (PsA) are at increased risk of herpes zoster (HZ), but healthcare resource use (HRU) and costs relating to HZ in adults with PsA are unknown. We aimed to estimate the incidence of HZ among adults with PsA vs without psoriatic disease and the additional HRU and costs among patients with PsA with vs without HZ.Patients and Methods: This retrospective, longitudinal, cohort study estimated HZ incidence in PsA+ vs PsO–/PsA– cohorts and HRU and medical/pharmacy costs among PsA+/HZ+ vs PsA+/HZ– cohorts comprised of adults from Optum’s de-identified Clinformatics Data Mart Database during 2015– 2020. For the HRU/cost analyses, index was the date of first HZ diagnosis (PsA+/HZ+ cohort) or was randomly assigned (PsA+/HZ– cohort). Generalized linear models were used for adjusted comparisons between cohorts.Results: HZ incidence was higher in the PsA+ (n = 57,126) vs PsO–/PsA– (n = 23,837,237) cohort (14.85 vs 7.67 per 1000 person-years; adjusted incidence rate ratio [aIRR]: 1.23; 95% confidence interval [CI]: 1.16– 1.30). Numbers of outpatient visits, emergency dep

Published
2024

48. Real-world patterns and sequences of targeted therapy use in chronic lymphocytic leukemia and small lymphocytic lymphoma in the United States: a longitudinal study.

Author

Huntington, Scott F., Cheng, Wendy Y., Sarpong, Eric M., Leng, Siyang, Farooqui, Mohammed Z. H., Agu, Uchechukwu Samuel, Catillon, Maryaline, Lejeune, Dominique, Downes, Nathaniel, Matay, Lisa, Duh, Mei Sheng, and De Nigris, Enrico

Subjects
CHRONIC lymphocytic leukemia, BRUTON tyrosine kinase, LYMPHOCYTIC leukemia, LYMPHOMAS, LONGITUDINAL method
Abstract

With increasing focus on novel targeted therapies for chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), this longitudinal claims-based study evaluated real-world CLL/SLL treatment sequences, particularly sequential targeted therapy. Among patients with first-line (1 L) treatment in 2014-2017 (N = 2,612; median follow-up = 3 years), the most common 1 L treatment was chemoimmunotherapy (CIT; 44.6%), followed by CD20 (25.2%) and Bruton's tyrosine kinase inhibitors (BTKi; 21.7%). Among those with 1 L in 2018-2021 (N = 4,534; median follow-up = 1 year), these were BTKi (45.5%), CD20 (20.4%), CIT (17.5%), and B-cell lymphoma 2 inhibitor (8.3%). In 2014-2017, the proportion of patients receiving sequential targeted therapy in the first 2 LOTs was 11.2% (80.2% was BTKi→BTKi); in 2018-2021, this proportion was 34.3% (66.4% was BTKi→BTKi). Over time, there was a substantial increase in targeted therapy use in 1 L and sequential targeted therapy, particularly with BTKi→BTKi. Future studies should assess clinical outcomes to determine optimal sequences for CLL/SLL and reasons for restarting BTKi. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results